Ocular Therapeutix, Inc. (OCUL) — Financial statements
Income statement, balance sheet, and cash flow for Ocular Therapeutix, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 52↓18.7% | 64↑9.0% | 58↑13.5% | 51↑18.3% | 44 | |
| Cost of Revenue | 7↑16.9% | 6↑6.5% | 5↑16.3% | 5↑3.0% | 4 | |
| Gross Profit | 45↓22.1% | 58↑9.3% | 53↑13.2% | 47↑20.0% | 39 | |
| Operating Expenses | ||||||
| R&D Expenses | 197↑54.4% | 128↑109.0% | 61↑14.2% | 53↑6.7% | 50 | |
| General & Administrative Expenses | 64↑6.1% | 61↑78.7% | 34↓50.1% | 68↑113.2% | 32 | |
| Selling & Marketing Expenses | 54↑29.7% | 42↑2.6% | 41↑873.3% | 4↓88.2% | 35 | |
| SG&A Expenses | 118↑15.7% | 102↑37.3% | 74↑3.2% | 72↑7.6% | 67 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 315↑37.2% | 230↑69.6% | 136↑7.9% | 126↑7.2% | 117 | |
| Total Costs & Expenses | 322↑36.7% | 236↑67.2% | 141↑8.2% | 130↑7.1% | 122 | |
| Operating Results | ||||||
| Operating Income | -270↓57.2% | -172↓108.5% | -82↓4.7% | -79↓0.8% | -78 | |
| Depreciation & Amortization | 4↑14.2% | 4↑26.9% | 3↑41.4% | 2↓12.9% | 2 | |
| EBITDA | -250↓41.8% | -176↓165.2% | -66↓7.3% | -62↓2538.2% | 3 | |
| EBIT | -254↓41.2% | -180↓159.3% | -69↓8.4% | -64↓54350.8% | 0.12 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↓2.8% | 7↑191.2% | -7↓18.2% | -6↑6.2% | -7 | |
| Interest Income | 18↓9.5% | 20↑409.2% | 4↑399.1% | 0.80↑2318.2% | 0.03 | |
| Interest Expense | 12↓12.8% | 14↑19.7% | 11↑61.5% | 7↑5.3% | 7 | |
| Non-Operating Income | -16↓295.3% | 8↑162.8% | -13↑11.3% | -15↑81.3% | -78 | |
| Other Income / Expenses | 4↑118.8% | -22↓1419.9% | 2↓78.4% | 8↓89.3% | 71 | |
| Income Before Tax | -266↓37.4% | -194↓139.7% | -81↓13.7% | -71↓984.1% | -7 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -266↓37.4% | -194↓139.7% | -81↓13.7% | -71↓984.1% | -7 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -266↓37.4% | -194↓139.7% | -81↓13.7% | -71↓984.1% | -7 | |
| Bottom-Line Net Income | -266↓37.4% | -194↓122.5% | -87↓8.3% | -80↓0.0% | -80 | |
| EPS (Basic) | -1.42↓16.4% | -1.22↓11.9% | -1.09↓4.8% | -1.04↑1.0% | -1.05 | |
| EPS (Diluted) | -1.42↓16.4% | -1.22↓19.6% | -1.02↓5.2% | -0.97↑1.0% | -0.98 | |
| Weighted Average Shares | 187↑18.3% | 158↑98.3% | 80↑3.8% | 77↑0.6% | 76 | |
| Weighted Average Diluted Shares | 187↑18.3% | 158↑84.9% | 86↑3.6% | 83↑0.6% | 82 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.